172 related articles for article (PubMed ID: 35225126)
1. Prediction of the risk for graft
Kamada Y; Arima N; Hayashida M; Nakamura D; Yoshimitsu M; Ishitsuka K
Leuk Lymphoma; 2022 Jul; 63(7):1701-1707. PubMed ID: 35225126
[TBL] [Abstract][Full Text] [Related]
2. Mogamulizumab Treatment Prior to Allogeneic Hematopoietic Stem Cell Transplantation Induces Severe Acute Graft-versus-Host Disease.
Sugio T; Kato K; Aoki T; Ohta T; Saito N; Yoshida S; Kawano I; Henzan H; Kadowaki M; Takase K; Muta T; Miyawaki K; Yamauchi T; Shima T; Takashima S; Mori Y; Yoshimoto G; Kamezaki K; Takenaka K; Iwasaki H; Ogawa R; Ohno Y; Eto T; Kamimura T; Miyamoto T; Akashi K
Biol Blood Marrow Transplant; 2016 Sep; 22(9):1608-1614. PubMed ID: 27220263
[TBL] [Abstract][Full Text] [Related]
3. Pretransplantation Anti-CCR4 Antibody Mogamulizumab Against Adult T-Cell Leukemia/Lymphoma Is Associated With Significantly Increased Risks of Severe and Corticosteroid-Refractory Graft-Versus-Host Disease, Nonrelapse Mortality, and Overall Mortality.
Fuji S; Inoue Y; Utsunomiya A; Moriuchi Y; Uchimaru K; Choi I; Otsuka E; Henzan H; Kato K; Tomoyose T; Yamamoto H; Kurosawa S; Matsuoka K; Yamaguchi T; Fukuda T
J Clin Oncol; 2016 Oct; 34(28):3426-33. PubMed ID: 27507878
[TBL] [Abstract][Full Text] [Related]
4. The Impact of a Humanized CCR4 Antibody (Mogamulizumab) on Patients with Aggressive-Type Adult T-Cell Leukemia-Lymphoma Treated with Allogeneic Hematopoietic Stem Cell Transplantation.
Kawano N; Kuriyama T; Yoshida S; Kawano S; Yamano Y; Marutsuka K; Minato S; Yamashita K; Ochiai H; Shimoda K; Ishikawa F; Kikuchi I
J Clin Exp Hematop; 2017; 56(3):135-144. PubMed ID: 28331127
[TBL] [Abstract][Full Text] [Related]
5. Prevention of acute graft-versus-host disease in adult T-cell leukemia-lymphoma patients who received mogamulizumab before allogeneic hematopoietic cell transplantation.
Inoue Y; Nishimura N; Murai M; Matsumoto M; Watanabe M; Yamada A; Izaki M; Nosaka K; Matsuoka M
Int J Hematol; 2022 Mar; 115(3):435-439. PubMed ID: 34705226
[TBL] [Abstract][Full Text] [Related]
6. Successful treatment with mogamulizumab followed by allogeneic hematopoietic stem-cell transplantation in adult T-cell leukemia/lymphoma: a report of two cases.
Tsubokura Y; Satake A; Hotta M; Yoshimura H; Fujita S; Azuma Y; Nakanishi T; Nakaya A; Ito T; Ishii K; Nomura S
Int J Hematol; 2016 Dec; 104(6):744-748. PubMed ID: 27573760
[TBL] [Abstract][Full Text] [Related]
7. Successful treatment strategy in corporating mogamulizumab and cord blood transplantation in aggressive adult T-cell leukemia-lymphoma: a case report.
Nakata K; Fuji S; Koike M; Tada Y; Masaie H; Yoshida H; Watanabe E; Kobayashi S; Tojo A; Uchimaru K; Ishikawa J
Blood Cell Ther; 2020 Feb; 3(1):6-10. PubMed ID: 37465376
[TBL] [Abstract][Full Text] [Related]
8. A Multicenter Retrospective Study of Mogamulizumab Efficacy in Adult T-Cell Leukemia/Lymphoma.
Iyama S; Sato T; Ohnishi H; Kanisawa Y; Ohta S; Kondo T; Mori A; Tsutsumi Y; Kuroda H; Kakinoki Y; Yamamoto S; Takahashi T; Shindo M; Torimoto Y; Sato K; Iwasaki H; Haseyama Y; Kohda K; Nagamachi Y; Hirayama Y; Sakai H; Hirata Y; Fukuhara T; Ikeda H; Kobune M; Kato J; Kurosawa M
Clin Lymphoma Myeloma Leuk; 2017 Jan; 17(1):23-30.e2. PubMed ID: 27727135
[TBL] [Abstract][Full Text] [Related]
9. Lenalidomide treatment for recurrent adult T-cell leukemia/lymphoma after allogeneic hematopoietic cell transplantation.
Tanaka T; Inamoto Y; Ito A; Watanabe M; Takeda W; Aoki J; Kim SW; Fukuda T
Hematol Oncol; 2023 Aug; 41(3):389-395. PubMed ID: 36513602
[TBL] [Abstract][Full Text] [Related]
10. Treatment with mogamulizumab or lenalidomide for relapsed adult T-cell leukemia/lymphoma after allogeneic hematopoietic stem cell transplantation: The Nagasaki transplant group experience.
Sakamoto H; Itonaga H; Sawayama Y; Furumoto T; Fujioka M; Chiwata M; Toriyama E; Kasai S; Nakashima J; Horai M; Kato T; Sato S; Ando K; Taguchi J; Imaizumi Y; Yoshida S; Hata T; Moriuchi Y; Miyazaki Y
Hematol Oncol; 2020 Apr; 38(2):162-170. PubMed ID: 31922287
[TBL] [Abstract][Full Text] [Related]
11. Cecum ulcer is a reliable endoscopic finding in cytomegalovirus colitis concomitant with graft-versus-host disease after allogeneic hematopoietic stem cell transplantation.
Matsuda K; Ono S; Ishikawa M; Miyamoto S; Abiko S; Tsuda M; Yamamoto K; Kudo T; Shimizu Y; Hayase E; Hashimoto D; Teshima T; Matsuno Y; Sakamoto N
Ann Hematol; 2018 May; 97(5):877-883. PubMed ID: 29340759
[TBL] [Abstract][Full Text] [Related]
12. Colonoscopy in the diagnosis of intestinal graft versus host disease and cytomegalovirus enteritis following allogeneic haematopoietic stem cell transplantation.
He JD; Liu YL; Wang ZF; Liu DH; Chen H; Chen YH
Chin Med J (Engl); 2008 Jul; 121(14):1285-9. PubMed ID: 18713549
[TBL] [Abstract][Full Text] [Related]
13. [Cytomegalovirus diseases after allogeneic hematopoietic stem cell transplantation (Allo-HSCT) and related risk factors].
Huang XJ; Xu LP; Ren HY; Zhang YC; Guo NL; Lu DP
Zhonghua Yi Xue Za Zhi; 2003 May; 83(9):766-9. PubMed ID: 12899755
[TBL] [Abstract][Full Text] [Related]
14. Detection of human cytomegalovirus (CMV) DNA in feces has limited value in predicting CMV enteritis in patients with intestinal graft-versus-host disease after allogeneic stem cell transplantation.
Sun YQ; Xu LP; Han TT; Zhang XH; Wang Y; Han W; Wang FR; Wang JZ; Chen H; Chen YH; Yan CH; Chen Y; Liu KY; Huang XJ
Transpl Infect Dis; 2015 Oct; 17(5):655-61. PubMed ID: 26275161
[TBL] [Abstract][Full Text] [Related]
15. Cytomegalovirus Reactivation after Allogeneic Hematopoietic Stem Cell Transplantation is Associated with a Reduced Risk of Relapse in Patients with Acute Myeloid Leukemia Who Survived to Day 100 after Transplantation: The Japan Society for Hematopoietic Cell Transplantation Transplantation-related Complication Working Group.
Takenaka K; Nishida T; Asano-Mori Y; Oshima K; Ohashi K; Mori T; Kanamori H; Miyamura K; Kato C; Kobayashi N; Uchida N; Nakamae H; Ichinohe T; Morishima Y; Suzuki R; Yamaguchi T; Fukuda T
Biol Blood Marrow Transplant; 2015 Nov; 21(11):2008-16. PubMed ID: 26211985
[TBL] [Abstract][Full Text] [Related]
16. Plasma exchange eliminates residual mogamulizumab but does not warrant prompt recovery of peripheral Treg levels.
Sugiura H; Matsuoka KI; Sando Y; Meguri Y; Ikegawa S; Nakamura M; Iwamoto M; Yoshioka T; Asano T; Kondo E; Fujii K; Fujii N; Maeda Y
Transfus Apher Sci; 2019 Aug; 58(4):472-474. PubMed ID: 31303512
[TBL] [Abstract][Full Text] [Related]
17. [Role of anti-CCR4 antibody in the treatment of transplant-eligible patients with aggressive adult T-cell leukemia/lymphoma].
Fuji S
Rinsho Ketsueki; 2018; 59(4):426-431. PubMed ID: 29743403
[TBL] [Abstract][Full Text] [Related]
18. [Cytomegalovirus enteritis after allogeneic hematopoietic stem cell transplantation].
Yin YM; Wu T; Ji SQ; Da WM; Zhao YL; Wang JB; Cao XY; Lu Y; Sun Y; Tong CR; Lu DP
Zhonghua Xue Ye Xue Za Zhi; 2011 Aug; 32(8):516-20. PubMed ID: 22338172
[TBL] [Abstract][Full Text] [Related]
19. Friend or foe? Mogamulizumab in allogeneic hematopoietic stem cell transplantation for adult T-cell leukemia/lymphoma.
Fuji S; Shindo T
Stem Cell Investig; 2016; 3():70. PubMed ID: 27868052
[TBL] [Abstract][Full Text] [Related]
20. Allogeneic hematopoietic stem cell transplantation after mogamulizumab in T-cell lymphoma patients: a retrospective analysis.
Lechowicz MJ; Smith C; Ristuccia R; Dwyer K
Int J Hematol; 2024 Mar; ():. PubMed ID: 38532079
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
